BR112022023438A2 - Tratamento de doença cardiometabólica com inibidores de sinalização de interferon tipo i - Google Patents

Tratamento de doença cardiometabólica com inibidores de sinalização de interferon tipo i

Info

Publication number
BR112022023438A2
BR112022023438A2 BR112022023438A BR112022023438A BR112022023438A2 BR 112022023438 A2 BR112022023438 A2 BR 112022023438A2 BR 112022023438 A BR112022023438 A BR 112022023438A BR 112022023438 A BR112022023438 A BR 112022023438A BR 112022023438 A2 BR112022023438 A2 BR 112022023438A2
Authority
BR
Brazil
Prior art keywords
treatment
signaling inhibitors
interferon type
cardiometabolic disease
type
Prior art date
Application number
BR112022023438A
Other languages
English (en)
Inventor
Sinibaldi Dominic
White Wendy
Smith Michael
Casey Kerry
Illei Gabor
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112022023438A2 publication Critical patent/BR112022023438A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

TRATAMENTO DE DOENÇA CARDIOMETABÓLICA COM INIBIDORES DE SINALIZAÇÃO DE INTERFERON TIPO I. A presente invenção descrição refere-se a métodos para o tratamento, ou para reduzir o risco de desenvolvimento, de um cardiometabólico em um paciente com o uso de um inibidor de sinalização de IFN tipo I.
BR112022023438A 2020-05-29 2021-05-28 Tratamento de doença cardiometabólica com inibidores de sinalização de interferon tipo i BR112022023438A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063031854P 2020-05-29 2020-05-29
PCT/EP2021/064312 WO2021239928A2 (en) 2020-05-29 2021-05-28 Treatment of cardiometabolic disease

Publications (1)

Publication Number Publication Date
BR112022023438A2 true BR112022023438A2 (pt) 2022-12-20

Family

ID=76269736

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023438A BR112022023438A2 (pt) 2020-05-29 2021-05-28 Tratamento de doença cardiometabólica com inibidores de sinalização de interferon tipo i

Country Status (10)

Country Link
US (1) US20240158519A1 (pt)
EP (1) EP4157873A2 (pt)
JP (1) JP2023527054A (pt)
KR (1) KR20230018446A (pt)
CN (1) CN115667309A (pt)
AU (1) AU2021279277A1 (pt)
BR (1) BR112022023438A2 (pt)
CA (1) CA3183611A1 (pt)
IL (1) IL298299A (pt)
WO (1) WO2021239928A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
WO2022223714A1 (en) 2021-04-23 2022-10-27 Astrazeneca Ab Anti-ifnar1 dosing regime for subcutaneous injection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
KR20100112206A (ko) 2002-04-11 2010-10-18 메디뮨 엘엘씨 분무 건조에 의한 생물학적 활성 물질의 보존
CA2849556A1 (en) 2002-04-11 2003-10-23 Vu Truong-Le Preservation of bioactive materials by freeze dried foam
AU2003230908A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
US7378110B2 (en) 2002-12-17 2008-05-27 Med Immune Vaccines, Inc. High pressure spray-dry of bioactive materials
SI1781705T1 (sl) 2004-06-21 2015-01-30 Medarex, L.L.C. Interferon alfa receptor i protitelesa in njihova uporaba
KR101666229B1 (ko) 2008-02-08 2016-10-14 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
PT2473636T (pt) 2009-09-03 2017-02-06 Medimmune Llc Diagnóstico de interferão de tipo-1
EP3769781B1 (en) 2015-08-19 2023-04-19 Astrazeneca AB Stable anti-ifnar1 formulation
SG11202104882WA (en) * 2018-11-15 2021-06-29 Ampel Biosolutions Llc Machine learning disease prediction and treatment prioritization

Also Published As

Publication number Publication date
CN115667309A (zh) 2023-01-31
CA3183611A1 (en) 2021-12-02
JP2023527054A (ja) 2023-06-26
EP4157873A2 (en) 2023-04-05
AU2021279277A1 (en) 2023-02-02
WO2021239928A9 (en) 2022-03-17
IL298299A (en) 2023-01-01
WO2021239928A3 (en) 2022-01-27
WO2021239928A2 (en) 2021-12-02
US20240158519A1 (en) 2024-05-16
KR20230018446A (ko) 2023-02-07

Similar Documents

Publication Publication Date Title
GEP20247607B (en) Nitrile-containing antiviral compounds
CL2020002026A1 (es) Inhibidor de fap.
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
CY1123387T1 (el) Συνδυασμος δυο αντιιικων για τη θεραπεια της ηπατιτιδας c
BR112022023438A2 (pt) Tratamento de doença cardiometabólica com inibidores de sinalização de interferon tipo i
CY1120417T1 (el) Μεθοδοι για τη μειωση των επιπεδων των βασεοφιλων
CY1125163T1 (el) 2΄-υποκατεστημενα-ν6-υποκατεστημενα πουρινο νουκλεοτιδια για την θεραπεια ιων rna
BR112022012112A2 (pt) Agonistas de il2 e métodos de uso dos mesmos
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
BR112017001162A2 (pt) métodos para tratar paramixovírus
BR112018075736A2 (pt) composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1
CL2022001406A1 (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
AU2019310335A8 (en) Methods of treating cancer with PI3K inhibitor, GDC-0077
CL2021001739A1 (es) Inhibidores de la proteína de activación de fibroblastos.
BR112021025537A2 (pt) Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica
BR112019009656A2 (pt) copolímeros diblocos automontados compostos por pegmema e segmentos poliméricos contendo fármacos
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
CO2022000270A2 (es) Inhibidores de enzimas
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2